Filing Details

Accession Number:
0000950170-24-098717
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-19 17:45:53
Reporting Period:
2024-08-15
Accepted Time:
2024-08-19 17:45:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1808592 Lisa Moltke Von C/O Seres Therapeutics, Inc.
101 Cambridge Park Drive
Cambridge MA 02140
See Remarks No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-15 2,969 $0.00 21,986 No 4 M Direct
Common Stock Disposition 2024-08-16 973 $0.84 21,013 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-08-15 2,969 $0.00 2,969 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
29,688 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  3. The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $0.890001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.